clinical trial · NCT06027086
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·recruiting·n = 27
Fibrolamellar Hepatocellular CarcinomaDurvalumabDRP-104
brief summary
The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).
started
Feb 12, 2024
primary completion
Sep 1, 2028
completion
Sep 1, 2033
last updated
Feb 12, 2026
official title
A Phase 1b/2 Study of Glutamine Antagonist DRP-104 in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Hepatocellular Carcinoma (FLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol